Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
26CA Stock Chart & Stats
€7.55
-€0.11(-4.34%)
At close: 4:00 PM EST
€7.55
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.63 - €10.40
Previous CloseN/A
Volume0.00
Average Volume (3M)5.18K
Market Cap
€7.51B
Enterprise Value€9.50B
Total Cash (Recent Filing)€242.82M
Total Debt (Recent Filing)€878.12M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 07, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,028,111,500
10 Day Avg. Volume3,062
30 Day Avg. Volume5,177
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.64Price Target Upside54.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€176.50M
Bulls Say, Bears Say
Bulls Say
Commercial Traction And International RolloutStrong commercial uptake in the United States, rising repeat prescribing, conditional European marketing authorization, and a dedicated EU distribution setup provide a platform for scalable sales growth.
Guideline InclusionInclusion of ANKTIVA plus BCG in national treatment guidelines expands the eligible patient pool beyond the current label and supports broader physician prescribing and insurer consideration.
Regulatory Pathway FlexibilityU.S. regulator's acceptance of a supplemental resubmission without requiring a new clinical trial signals regulatory flexibility and reduces near‑term approval risk for label expansion.
Bears Say
Regulatory Trial Requirement RiskPotential requirement for a randomized trial in the papillary‑only setting creates significant regulatory uncertainty and could delay formal approval for that indication.
Reimbursement And Payer Access RiskIndependent payer coverage and reimbursement decisions may be slow or limited for a papillary‑only indication, which could restrict patient access even after regulatory approval.
Supply And Launch Execution UncertaintyShortages of traditional BCG combined with variable national reimbursement timelines and unclear European launch pacing could hinder market penetration and postpone revenue realization outside core markets.
ImmunityBio News
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.63 and its highest was €10.40 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is €7.51B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is May 07, 2026 which is in 46 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Mar 03, 2026. The company reported -€0.052 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.015.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.06.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,028,111,500 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.052 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went down -3.901%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in DE:26CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.64 (54.21% Upside)
€11.64 (54.21% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 83%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
208.00%
12-Months-Change
Fundamentals
Return on Equity
64.30%
Trailing 12-Months
Asset Growth
31.07%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.View all DE:26CA earnings summaries26CA Stock 12 Month Forecast
Average Price Target
€11.64
▲(54.21% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---